12 Best Upside Stocks to Buy Now

Page 5 of 11

7. Dyne Therapeutics Inc. (NASDAQ:DYNE)

Number of Hedge Fund Holders: 45

Average Upside Potential as of November 27: 79.50%

Dyne Therapeutics Inc. (NASDAQ:DYNE) is one of the best upside stocks to buy now. On November 25, Bernstein raised the firm’s price target on Dyne Therapeutics to $21 from $12 with a Market Perform rating on the shares. Bernstein believes that Dyne Therapeutics has a favorable risk-reward profile. The next major catalyst expected for the company is the release of data for the registrational expansion cohort of DYN-251, which is a treatment candidate for Duchenne Muscular Dystrophy/DMD.

In its Q3 2025 earnings report, Dyne Therapeutics disclosed that both of its lead programs, zeleciment rostudirsen (z-rostudirsen, or DYNE-251) for DMD and zeleciment basivarsen (z-basivarsen, or DYNE-101) for Myotonic Dystrophy Type 1/DM1, had been granted Breakthrough Therapy Designation by the FDA. This dual progress reinforces the potential of the FORCE platform to deliver drug payloads effectively to the muscle and the central nervous system/CNS.

Dyne expects to launch two potentially best-in-class medicines within ~one year of each other, starting with z-rostudirsen.DYNE-251 for DMD. The company is also on track to announce topline data from the 6-month primary analysis in December 2025. These data, along with comprehensive data from the multiple ascending dose/MAD portion of the trial, are expected to support a potential submission for US Accelerated Approval in Q2 2026.

Dyne Therapeutics Inc. (NASDAQ:DYNE) is a clinical-stage neuromuscular disease company that discovers and develops therapeutics for neuromuscular diseases in the US.

Page 5 of 11